Location History:
- Vanløse, DK (2013)
- Vanlose, DK (2018)
- Frederiksberg, DK (2020 - 2021)
- Vanloese, DK (2014 - 2022)
Company Filing History:
Years Active: 2013-2022
Title: The Innovative Contributions of Ida Hilden
Introduction
Ida Hilden is a prominent inventor based in Vanloese, Denmark. She has made significant contributions to the field of biomedicine, particularly in the development of novel therapeutic antibodies. With a total of 13 patents to her name, Hilden's work has the potential to impact the treatment of coagulopathies and other related conditions.
Latest Patents
One of Hilden's latest patents involves antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161). This application discloses bispecific TFPI antibodies that can specifically and simultaneously bind two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralizing TFPI, even when the concentration of TFPI is elevated. These antibodies or compositions comprising them may be utilized for treating subjects with coagulopathy. Another significant patent describes coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets. This patent outlines procoagulant proteins, which may include fusion proteins or chemical conjugates, and methods for producing these proteins. The described procoagulant proteins can be used as a medicament for individuals suffering from coagulopathies, such as hemophilia A and B, with or without inhibitors.
Career Highlights
Ida Hilden has worked with notable companies in the pharmaceutical industry, including Novo Nordisk A/S and Novo Nordisk Healthcare AG. Her experience in these organizations has contributed to her expertise in developing innovative therapeutic solutions.
Collaborations
Hilden has collaborated with esteemed colleagues such as Jes Thorn Clausen and Jens Breinholt. These partnerships have likely enhanced her research and development efforts in the field of biomedicine.
Conclusion
Ida Hilden's innovative work in the development of bispecific antibodies and procoagulant proteins showcases her significant contributions to medical science. Her patents reflect a commitment to advancing treatments for coagulopathies, which could greatly benefit patients in need.